Cargando…

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)

Detalles Bibliográficos
Autores principales:	Perfetti, F, Gesualdo, F, Messia, V, Insalaco, A, Bracaglia, C, Pardeo, M, Nicolai, R, Meli, L, De Benedetti, F, Magni Manzoni, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044940/ http://dx.doi.org/10.1186/1546-0096-11-S2-P154

Ejemplares similares

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

PReS-FINAL-2202: A novel PSMB8 mutation associated with CANDLE syndrome
por: Insalaco, A, et al.
Publicado: (2013)

PReS-FINAL-2200: Phenotype of V198M and Q703K NLRP3 variants
por: Messia, V, et al.
Publicado: (2013)

P01-050 – Anakinra in systemic JIA: single center experience
por: Pardeo, M, et al.
Publicado: (2013)

PReS-FINAL-2201: A P268S NOD mutation in one Blau patient
por: Pardeo, M, et al.
Publicado: (2013)

P02-016 - A novel PSMB8 mutation causing candle syndrome
por: Messia, V, et al.
Publicado: (2013)

P02-031 - Phenotype of V198M and Q703K NLRP3 variants
por: Messia, V, et al.
Publicado: (2013)

PReS-FINAL-2359: Renal involvement in hypocomplementemic urticarial vasculitis syndrome (huvs): report of 3 paediatric cases
por: Bracaglia, C, et al.
Publicado: (2013)

PReS-FINAL-2199: A novel mutation in the CIAS1/NLRP3 gene associated with an unusual phenotype of CAPS
por: Insalaco, A, et al.
Publicado: (2013)

Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra
por: Pardeo, M, et al.
Publicado: (2015)

The role of steroid injection in joints and tendon sheaths in JIA in the biologic era
por: Messia, Virginia, et al.
Publicado: (2014)

P03-012 - A P268S NOD2 mutation in one Blau patient
por: Pardeo, M, et al.
Publicado: (2013)

PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
por: Pratsidou-Gertsi, P, et al.
Publicado: (2013)

Involvement of the IFN-gamma pathway in a patient with candle syndrome carrying a novel variant of PSMB8 gene
por: Insalaco, Antonella, et al.
Publicado: (2014)

P02-032 - CAPS: a novel mutation and an unusual phenotype
por: Insalaco, A, et al.
Publicado: (2013)

Clinical presentation and cytokine production abnormalities in a cohort of patients carrying NLRP12 gene variants
por: Insalaco, Antonella, et al.
Publicado: (2014)

PReS-FINAL-2102: Comparison of sensitivity and specificity of MAS and HLH diagnostic guidelines in 362 children with MAS complicating systemic JIA
por: Davì, S, et al.
Publicado: (2013)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
por: Bracaglia, C, et al.
Publicado: (2008)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Chemical attribution of the homemade explosive ETN - Part II: Isotope ratio mass spectrometry analysis of ETN and its precursors
por: Bezemer, Karlijn, et al.
Publicado: (2020)

Single center experience in Next Generation Sequencing for genetic diagnosis of Autoinflammatory Disorders (AIDs)
por: Lepri, FR, et al.
Publicado: (2015)

Low levels of the nerve growth factor receptor TrkA in JIA: a possible defect in a novel anti-inflammatory mechanism
por: Minnone, G, et al.
Publicado: (2011)

Low levels of the nerve growth factor receptor TrkA in JIA: a possible defect in a novel anti-inflammatory mechanism
por: Minnone, G, et al.
Publicado: (2011)

PReS-FINAL-2050: Determination of the concentration of methotrexate in the blood serum of patients with JIA
por: Rokhlina, F, et al.
Publicado: (2013)

Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus
por: De Matteis, Arianna, et al.
Publicado: (2021)

PReS-FINAL-2186: Monoallelic mutations of familial hlh-related genes associated to macrophage activation syndrome
por: Bracaglia, C, et al.
Publicado: (2013)

PReS-FINAL-2055: Is there a necessity for patients with JIA to wear orthopedic insoles?
por: Kreuzpointner, F, et al.
Publicado: (2013)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
por: Jaworski, Janusz, et al.
Publicado: (2019)

PReS13-SPK-1576: Unmeet needs in JIA treatment
por: Ruperto, N
Publicado: (2013)

PReS-FINAL-2254: Is it systemic JIA or post infectious illness?
por: Guddeti, P, et al.
Publicado: (2013)

PReS-FINAL-1007: Regulatory T cells functional specialization in JIA
por: Mijnheer, G, et al.
Publicado: (2013)

Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014)

The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
por: Trachana, M, et al.
Publicado: (2008)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Etanercept therapy in JIA: impact on the need for intra-articular steroid injections
por: Pain, CE, et al.
Publicado: (2008)

DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011)

Whole-Body MRI versus bone scintigraphy: which is the best diagnostic tool in patients with chronic recurrent multifocal osteomyelitis (CRMO)?
por: Villani, MF, et al.
Publicado: (2015)

Chronic recurrent multifocal osteomyelitis (CRMO): typical patterns of bone involvement on MRI with particular emphasis on Whole Body MRI (WBMRI)
por: de Horatio, L Tanturri, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p6kal4nqo05kfu0rr2m59s3u9c